1. Gene sequencing is the basis for the development of precision medical industry, and it is also a mature field for the commercial application of precision medical industry.
The gene sequencer is a key link in the gene sequencing industry chain. Upstream genetic testing is a sequencing instrument and reagent consumables. The middle and lower reaches are gene sequencing services and bioinformatics analysis for hospitals, pharmaceutical companies, research institutions, and consumers. The gene sequencer is the starting point and key link of the sequencing industry chain. It provides the most basic sequencing support for the entire midstream and downstream sequencing services.
.jpg)
The core of the genetic sequencer is sequencing technology. Since the first genetic sequencer was introduced in 1985, gene sequencing technology has been continuously developed, and the cost of sequencing has been reduced, making gene sequencing gradually move from the scientific research stage to commercial application. Up to now, gene sequencing technology has developed into a three-generation sequencing technology, and the current large-scale commercial application is the second generation sequencing technology.
.jpg)
The genetic sequencer has high technical barriers and is basically monopolized by foreign companies. The gene sequencer is at the top of the entire gene sequencing industry chain and is the highest part of the value chain. The global genetic sequencer market has been monopolized by Illumina, Life Technology and Roche, and the three companies are close to controlling the global upstream of the entire genetic testing industry. China has continuously increased R&D investment in the field of sequencers, trying to break the existing monopoly situation in the market of the sequencer, but there are still technical problems to be broken. In 2013, Huada Gene invested US$118 million to acquire Complete Genomics in the United States and launched the BGI-SEQ 500 sequencer and Revolocity system (in a state of suspension).
.jpg)
Sequencing consumables are the breakthrough point for Chinese companies in the upstream of the sequencing market. Compared with the sequencer, the technical barriers of the sequencing consumables are relatively low, and the R&D investment is relatively small. This makes the domestic gene sequencing enterprises involved in the upstream field of genetic testing with the detection kit and the sequencer jointly reporting the CFDA registration. In November 2014, the CFDA approved the DAA gene gene sequencer and the fetal chromosome aneuploidy 21 trisomy, 18 trisomy and trisomy 13 (semiconductor sequencing) medical device registration. In 2015, Berry and Kang's gene sequencer (NextSeq CN500) and fetal chromosome aneuploidy (T13/T18/T21) test kits were approved by CFDA medical device products, and gradually implemented in the genetic testing upstream industry.
.jpg)
Butyl Rubber Stopper For Film Coated
We are a chinese origin manufacturer , we majored in producing rubber products for almost 10 years , which allows us to offer a wide range products for you . Our products now are widely used in clinical injection, transfusion and other packaging. We now have a 100-100000 class cleaning workshop which meets the GMP standard. From input to output, we have a strict quality control throughout the whole production line. We have full test instruments and tools according to the standard documents.
Butyl Rubber Stopper For Film Coated,Stopper For Film Coated,Silicone Rubber Stopper,Butyl Bottles Silicone Rubber Stopper
SUZHOU CRH PHARMACEUTICAL TECHNOLOGY CO.,LTD , https://www.crh-health.com